prinomastat + gemcitabine + cisplatin

The combination of **prinomastat, gemcitabine, and cisplatin** is an investigational regimen primarily explored for use in oncology, notably in pancreatic cancer and potentially other solid tumors. - **Prinomastat** is a small molecule matrix metalloproteinase (MMP) inhibitor targeting several MMPs involved in tumor invasion and metastasis, including MMP-2, MMP-9, and MMP-14, thereby inhibiting processes such as extracellular matrix degradation and angiogenesis. - **Gemcitabine** is a nucleoside analogue antimetabolite that interferes with DNA synthesis through inhibition of DNA polymerase and ribonucleotide reductase, leading to cytotoxicity in rapidly dividing cells. - **Cisplatin** is a platinum-based compound that forms DNA crosslinks, inducing apoptosis in cancer cells due to DNA damage. The combination regimen is typically administered intravenously and has been studied for its enhanced antitumor effect through simultaneous inhibition of cell proliferation, induction of apoptosis, and reduction of tumor invasiveness. The triple combination has been most studied in early phase clinical trials, often in the context of advanced pancreatic cancer, as part of multi-agent chemotherapy regimens building on the benefit observed with gemcitabine and cisplatin doublets.